RRG001 / Refreshgene Therap - LARVOL DELTA

Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) (clinicaltrials.gov) - P1/2 | N=48 | Recruiting | Sponsor: Shanghai Refreshgene Technology Co., Ltd. | Trial primary completion date: Dec 2027 ➔ Apr 2026

Gene therapy • Trial primary completion date • Age-related Macular Degeneration • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

The Preliminary Safety and Efficacy of RRG001 After Vitrectomy in Subjects With Proliferative Diabetic Retinopathy (PDR) (clinicaltrials.gov) - P1 | N=6 | Recruiting | Sponsor: Li Xiaorong

New P1 trial • Diabetic Retinopathy • Retinal Disorders

RRG001: Innovative Anti-VEGF AAV Gene Therapy for Retinal Disease (ASGCT 2024) - "Our RRG-001 is a safe, well-tolerated and long-lasting drug for neovascularization inhibition in PRNV monkey model.Plain Language Summary: DL-AAA induced persistent retinal neovascularization is an effective model for evaluating long-lasting therapeutic efficiency. Our AAV based anti-VEGF drug RRG-001 has inhibits neovascularization more than 46 weeks in DL-AAA induced PRVN monkeys, which is proved to be a safe, well-tolerated and long-lasting drug for neovascularization inhibition."

Gene therapy • Age-related Macular Degeneration • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) (clinicaltrials.gov) - P1/2 | N=48 | Recruiting | Sponsor: Shanghai Refreshgene Technology Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Gene therapy • Age-related Macular Degeneration • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration